Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by janfebbounceon Jan 16, 2019 10:55am
100 Views
Post# 29239357

cheapest MJ play, which haven't move as yet

cheapest MJ play, which haven't move as yet

 

Calyx finishes developing Canadian cannabis exchange

 

2018-11-20 12:10 ET - News Release

 

Mr. Roger Forde reports

CALYX COMPLETES DEVELOPMENT OF CANADIAN CANNABIS MARKETPLACE PLATFORM

Calyx Ventures Inc. has completed the development of its Canadian cannabis exchange platform. Calyx's wholly owned subsidiary, Cannigistics Agri-Solutions Corp., has completed the wholesale component of the application and is now ready to proceed with the identification of third party partners for the testing of the platform.

"As the cannabis landscape matures, the necessity for an independent, fluid marketplace is becoming increasingly more apparent," explained Roger Forde, chief executive officer of Calyx. "To this end, we are building an infrastructure which will allow for any current and future licensed producers, distributors and extractors to get their product to market quickly, efficiently and affordably."

The wholesale and marketplace system was developed based on a proven and tested model currently in service in the Canadian agricultural marketplace. In addition to the company's extensive development and customization of this model to date, the final application framework includes a private distributed ledger to handle and track contracts and transactions.

"Blockchain technology is naturally suited to marketplace applications. This particular market has a need for transaction verification and transparency, so we feel that building the platform to include a private blockchain ledger will give it transparency with both market participants and regulatory authorities," Mr. Forde said. "We see great opportunity in the cannabis market for efficiency, liquidity and accountability, and intend to provide these features through our platform."

Bullboard Posts